Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma – PRNewswire
Searching for your content… In-Language News Contact Us 888-776-0942 from 8 AM – 10 PM ET Updated results of weekly and biweekly dosing of talquetamab monotherapy and initial results in combination with daratumumab presented in…




